TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · major macro event coming up
EXEL

Exelixis Inc

Healthcare · Biotechnology

53.00$ -2.1% vs. previous close Closing price · As of: Aug 10, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Exelixis Inc (EXEL). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — EXEL
Segment 2022 2023 2024 2025
Reportable Segment $1.61B 100.0% $1.83B 100.0% · +13.6% $2.17B 100.0% · +18.5% $2.32B 100.0% · +7.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — EXEL
Segment 2020 2021 2022 2023 2024 2025
U.S. $752.9M 76.2% $1.09B 75.9% · +44.7% $1.41B 87.8% · +29.8% $1.65B 89.9% · +16.4% $1.82B 84.1% · +10.8% $2.14B 92.3% · +17.4%
Europe $151.6M 15.4% $302.1M 21.1% · +99.2% $168.6M 10.5% · -44.2% $145.0M 7.9% · -14.0% $318.6M 14.7% · +119.8% $154.2M 6.6% · -51.6%
Japan $83.0M 8.4% $43.5M 3.0% · -47.6% $28.7M 1.8% · -34.0% $39.5M 2.2% · +37.5% $27.1M 1.2% · -31.4% $25.6M 1.1% · -5.5%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 10, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?